In a rat model of PD, tacrolimus was shown to cross the BBB, alter phosphorylation of GAP-43 and BASP1, and confer neuroprotection at doses 10-fold lower than the standard immunosuppressive dose (Caraveo et al., 2017). The gene discussed is BASP1; the disease is Parkinson disease.